Updated clinical recommendations for the use of tibolone in Asian women

Climacteric

Volumn 13, Issue 4, 2010, Pages 317-327

  Huang, K E ^a   Baber, R ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Asian; Postmenopausal; Review; Tibolone; Treatment algorithm

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TIBOLONE; PREGNANE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTHRALGIA; ASIAN; AUSTRALIA; BONE PAIN; BREAST CANCER; BREAST TENDERNESS; CANCER RECURRENCE; CANCER RISK; CARDIOVASCULAR RISK; CHINA; CHOLESTEROL BLOOD LEVEL; COGNITION; COMPARATIVE STUDY; DYSPAREUNIA; FEMALE; HEALTH SURVEY; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INDIA; INDONESIA; INSOMNIA; KOREA; MALAYSIA; MASTALGIA; MENOPAUSAL SYNDROME; MENOPAUSE; MINI MENTAL STATE EXAMINATION; NIGHT SWEAT; OSTEOLYSIS; PHILIPPINES; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SINGAPORE; TAIWAN; THAILAND; VAGINA BLEEDING; VAGINAL DRYNESS; VERTEBRA FRACTURE; VIET NAM; ATTITUDE TO HEALTH; BREAST TUMOR; CARDIOVASCULAR DISEASE; CONTRAINDICATIONS; ESTROGEN THERAPY; HOT FLASHES; MIDDLE AGED; MUSCULOSKELETAL DISEASES; OSTEOPOROSIS, POSTMENOPAUSAL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RURAL POPULATION; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SLEEP INITIATION AND MAINTENANCE DISORDERS; URBAN POPULATION;

ARTHRALGIA; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; ESTROGEN RECEPTOR MODULATORS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOT FLASHES; HUMANS; MIDDLE AGED; MUSCULOSKELETAL DISEASES; NORPREGNENES; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RURAL POPULATION; SEXUAL DYSFUNCTIONS, PSYCHOLOGICAL; SLEEP INITIATION AND MAINTENANCE DISORDERS; URBAN POPULATION;

EID: 77953563414     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697131003681458     Document Type: Review

References (62)

1. Kenemans P. Tibolone: how does its mechanism of action translate into clinical effects. Maturitas 2004;48(Suppl 1): S1-3
2. Gompel A, Chaouat M, Jacob D, et al. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351-359
3. Hammar M, Christau S, Nathorst-Boos J, et al. A doubleblind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904-911
4. Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002; 109:886-893
5. Baracat EC, Barbosa IC, Giordano MG, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002;5:60-69
6. Nathorst-Boos J, Hammar M. Effect on sexual life - a comparison between tibolone and a continuous estradiolnorethisterone acetate regimen. Maturitas 1997;26:15-20
7. Castelo-Branco C, Vicente JJ, Figueras F, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 2000;34:161-168
8. Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, et al. Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. J Sex Med 2008;5:646-656
9. Egarter C, Topcuoglu A, Vogl S, et al. Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women. Acta Obstet Gynecol Scand 2002;81:649-653
10. Somunkiran A, Erel CT, Demirci F, et al. The effect of tibolone versus 17beta-estradiol on climacteric symptoms in women with surgical menopause: a randomized, crossover study. Maturitas 2007;56:61-68
11. Egarter C, Sator M, Berghammer P, et al. Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women. Int J Gynaecol Obstet 1999; 64:281-286
12. Meeuwsen IB, Samson MM, Duursma SA, et al. The effect of tibolone on fat mass, fat-free mass, and total body water in postmenopausal women. Endocrinology 2001;142: 4813-4817
13. Volker W, Coelingh Bennink HJ, Helmond FA. Effects of tibolone on the endometrium. Climacteric 2001;4: 203-208
14. Wender MC, Edelweiss MI, Campos LS, et al. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. Menopause 2004;11:423-429
15. Fedele L, Bianchi S, Raffaelli R, et al. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. Eur J Obstet Gynecol Reprod Biol 2000;88:91-94
16. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med 2008;359:697-708
17. Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-722
18. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast cancer patients with vasomotor symptoms: a double-blind, randomised, noninferiority trial. Lancet Oncol 2009;10:135-146
19. Boulet MJ, Oddens BJ, Lehert P, et al. Climacteric and menopause in seven South-east Asian countries. Maturitas 1994;19:157-176
20. Huang KE, Ling X, Jaisamram U, et al. A multinational survey of Asian menopausal women. Presented at XVIII FIGO World Congress of Gynaecology and Obstetrics; 2006, Kuala Lumpur, Malaysia
21. Asia Pacific Menopause Federation. Asia-Pacific Menopause Federation consensus statement on the management of the menopause, April 2008. Available at: www.apmf. net/
22. Speroff L, Kenemans P, Burger HG. Practical guidelines for postmenopausal hormone therapy. Maturitas 2005;51:4-7 (Pubitemid 40692592)
23. Pines A, Sturdee DW, Birkhauser MH, et al. IMS updated recommendations on postmenopausal hormone therapy. Climacteric 2007;10:181-194 (Pubitemid 46752441)
24. Utian WH, Archer DF, Bachmann GA, et al. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602
25. Kenemans P, Speroff L. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. Maturitas 2005;51: 21-28
26. Haines CJ, Rong L, Chung TK, et al. The perception of the menopause and the climacteric among women in Hong Kong and southern China. Prev Med 1995;24: 245-248
27. Haines CJ, Xing SM, Park KH, et al. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitas 2005;52:264-276
28. Pan HA, Wu MH, Hsu CC, et al. The perception of menopause among women in Taiwan. Maturitas 2002;41:269-274
29. Zhao G, Wang L, Yan R, et al. Menopausal symptoms: experience of Chinese women. Climacteric 2000;3: 135-144
30. Choi H, Lee HK, Park HM. The Korean menopausal women's attitudes and awareness on menopause. J Korean Soc Menopause 2003;9:36-43
31. Freeman EW, Sherif K. Prevalence of hot flushes and night sweats around the world: a systematic review. Climacteric 2007;10:197-214
32. Genazzani AR, Schneider HP, Panay N, et al. The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy. Gynecol Endocrinol 2006;22:369-375
33. Dhillon HK, Singh HJ, Ghaffar NA. Sexual function in menopausal women in Kelantan, Malaysia. Maturitas 2005;52:256-263
34. Hammar ML, van de Weijer P, Franke HR, et al. Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. Br J Obstet Gynaecol 2007;114:1522-1529
35. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911-918
36. Delmas PD, Davis SR, Hensen J, et al. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporos Int 2008;19:1153-1160
37. Renoux C, Dell'aniello S, Garbe E, et al. Hormone replacement therapy use and the risk of stroke. Maturitas 2008;61:305-309
38. Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. Eur Heart J 2006;27:746-755
39. Clarkson TB. Does tibolone exacerbate atherosclerosis? Eur Heart J 2006;27:635-637
40. Lokkegaard E, Andreasen AH, Jacobsen RK, et al. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J 2008;29:2660-2668
41. Opatrny L, Dell'Aniello S, Assouline S, et al. Hormone replacement therapy use and variations in the risk of breast cancer. Br J Obstet Gynaecol 2008;115:169-75; discussion 175 (Pubitemid 350233601)
42. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-427
43. Pan HA, Wang ST, Pai MC, et al. Cognitive function variations in postmenopausal women treated with continuous, combined HRT or tibolone. A comparison. J Reprod Med 2003;48:375-380
44. Wu MH, Pan HA, Wang ST, et al. Quality of life and sexuality changes in postmenopausal women receiving tibolone therapy. Climacteric 2001;4:314-319
45. Yang TS, Tsan SH, Chen CR, et al. Evaluation of conjugated estrogen plus medroxyprogesterone acetate versus tibolone in early postmenopausal Chinese women. Chinese Med J (Taipei) 1999;62:308-315
46. Lam PM, Cheung GW, Shek DT, et al. A randomized, placebo-controlled, crossover study of tibolone (Livial) on menopause symptoms, psychological wellbeing, and dyadic relationship of postmenopausal Chinese women and their spouses. Menopause 2004; 11:416-422
47. Koh KK, Ahn JY, Jin DK, et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 2003;23: 1889-1894
48. White RH, Keenan CR. Effects of race and ethnicity on the incidence of venous thromboembolism. Thromb Res 2009; 123(Suppl 4):S11-17
49. Tan KS, Rashid A, Tan CT. Venous thromboembolism in ischaemic stroke in Asia. Neurol Asia 2008;13:95-101
50. Heit JA. Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 2005;3: 1611-1617
51. Greendale GA, Reboussin BA, Sie A, et al. Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators. Ann Intern Med 1999;130:262-269
52. Habel LA, Capra AM, Oestreicher N, et al. Mammographic density in a multiethnic cohort. Menopause 2007;14:891-899
53. Valdivia I, Campodonico I, Tapia A, et al. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 2004;81: 617-623
54. Bruce D, Robinson J, McWilliams S, et al. Long-term effects of tibolone on mammographic density. Fertil Steril 2004;82:1343-1347
55. Howick J, Phillips B, Ball C, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Oxford Centre for Evidence-based Medicine Levels of Evidence. 2009. Available at: http://www.cebm.net/index.aspx?o= 1025
56. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-1551
57. de Vries CS, Bromley SE, Thomas H, et al. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK. Drug Safety 2005;28:241-319
58. Koh LK, Sedrine WB, Torrelba TP, et al. A simple tool to identify Asian Women at increased risk of osteoporosis. Osteoporos Int 2001;12:699-705
59. Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-397
60. Chow SN, Huang CC, Lee YT. Demographic characteristics and medical aspects of menopausal women in Taiwan. J Formos Med Assoc 1997;96:806-811
61. Nijland EA, Nathorst-Boos J, Palacios S, et al. Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. Climacteric 2009;12:114-121
62. Nijland EA, Weijmar Schultz WC, Davis SR. Effects of tibolone and raloxifene on health-related quality of life and sexual function. Maturitas 2007;58:164-173